This post was written by Nicolle Rueras.
A recent court case between the Indian Government and pharmaceutical company, Novartis, has caused a stir in the global community. Novartis is challenging Section 3(d) of India’s Patent Act, which requires companies to prove that their drug is more successful than alternative treatments for a disease to receive or extend a patent.
To get around this regulation, many companies begin “evergreening” – making minor changes to a drug that may not improve its efficacy but claim it does in order to extend its patent. If Novartis succeeds, this may open the door for other companies to follow suit, ultimately driving up prices for crucial medicines produced in India and needed around the world.